AtaiBeckley (ATAI) Q1 2026 earnings summary

Executive summary

• Net loss attributable to stockholders was $29.8 million for Q1 2026, up from $26.4 million in Q1 2025, reflecting increased R&D and G&A expenses.

• Revenue for Q1 2026 was $0.95 million, down 39% year-over-year, driven by lower research and development services revenue.

• The company completed a redomiciliation to the U.S. and integrated Beckley Psytech, expanding its pipeline in mental health treatments.

Financial highlights

• Total revenue: $0.95 million in Q1 2026 vs. $1.56 million in Q1 2025.

• Research and development expenses increased 54% to $17.4 million; general and administrative expenses rose 36% to $14.4 million.

• Cash and cash equivalents were $43.1 million, and short-term securities were $166.8 million as of March 31, 2026.

• Accumulated deficit reached $1.4 billion.

• Net cash used in operating activities was $21.1 million for Q1 2026.

Outlook and guidance

• Existing cash, cash equivalents, and short-term securities are expected to fund operations for at least the next 12 months and into 2029 based on current plans.

• Continued focus on advancing clinical programs, with Phase 3 trials for BPL-003 and Phase 2 for VLS-01 and EMP-01 on track.